RDGL VIVOS INC
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1449349 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY392.2%
TTM net income YoY-27.1%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR69.3%
Net income 3-yr CAGR—
Margins
Gross margin6.8%
Operating margin-2,414.0%
Net margin-3,032.9%
FCF margin—
EBITDA margin—
Returns
ROE-180.2%
ROA-167.1%
ROIC (approx.)-2,040.3%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets9.7%
Debt / equity0.00x
Current ratio12.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-66.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $28,900 | $36,400 | $36,068 | $24,752 | $1,879 | $15,000 | $26,748 | -$18,005 |
| Cost of revenue | $7,438 | $38,120 | $44,086 | $27,857 | $14,694 | $49,753 | $35,831 | $10,280 |
| Gross profit | $21,462 | -$1,720 | -$8,018 | -$3,105 | -$12,815 | -$34,753 | -$9,083 | -$5,285 |
| R&D expense | $31,802 | $49,182 | $37,923 | $57,166 | $67,820 | $107,965 | $119,281 | $100,969 |
| SG&A expense | $203,455 | $82,278 | $58,685 | $90,535 | $72,904 | $80,913 | $52,203 | $98,356 |
| Operating income | -$748,838 | -$654,529 | -$545,492 | -$1.10M | -$531,023 | -$674,773 | -$863,532 | -$661,800 |
| Pretax income | -$731,594 | -$830,189 | -$1.18M | -$1.08M | -$507,294 | -$645,513 | -$834,696 | -$1.02M |
| Net income | -$731,594 | -$830,189 | -$1.18M | -$1.08M | -$507,294 | -$645,513 | -$834,696 | -$1.02M |
| EBITDA | -$740,639 | -$654,171 | -$535,531 | — | — | — | — | — |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 494.29M | 490.70M | 462.16M | — | 454.30M | 453.51M | 448.23M | — |
| Banking | ||||||||
| Net interest income | $17,244 | $20,340 | $12,275 | $17,205 | $23,729 | $29,260 | $28,836 | $19,612 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.81M | $2.34M | $2.53M | $1.56M | $2.20M | $2.66M | $3.27M | $2.21M |
| Receivables | $27,825 | $15,650 | $7,668 | $22,331 | $4,699 | $13,270 | $8,704 | $10,326 |
| Inventory | $55,997 | $56,427 | $56,863 | $57,257 | $62,734 | $62,961 | $21,198 | — |
| Current assets | $1.91M | $2.44M | $2.60M | $1.65M | $2.30M | $2.78M | $3.30M | $2.23M |
| PP&E, net | $277,433 | $338,236 | $244,055 | $102,811 | — | — | — | — |
| Total assets | $2.28M | $2.88M | $2.95M | $1.87M | $2.30M | $2.78M | $3.30M | $2.23M |
| Current liabilities | $155,179 | $49,973 | $171,737 | $117,892 | $112,693 | $96,458 | $115,378 | $86,209 |
| Total liabilities | $221,600 | $123,955 | $253,195 | $206,743 | $112,693 | $96,458 | $115,378 | $86,209 |
| Shareholders' equity | $2.06M | $2.76M | $2.70M | $1.66M | $2.18M | $2.68M | $3.19M | $2.15M |
| Shares outstanding | 494.74M | 494.21M | 482.84M | 455.49M | 454.66M | 453.80M | 453.41M | 440.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$593,394 | -$739,580 | -$429,861 | -$539,554 | -$458,481 | -$604,510 | -$455,198 | -$470,912 |
| Capital expenditure | -$52,604 | $94,539 | $151,205 | — | — | — | — | — |
| Free cash flow | -$540,790 | -$834,119 | -$581,066 | — | — | — | — | — |
| Investing cash flow | $52,604 | -$94,539 | -$151,205 | — | — | — | — | — |
| Financing cash flow | $12,118 | $644,359 | $1.55M | -$845 | $0 | $0 | $1.51M | $1.47M |
| Depreciation & amortization | $8,199 | $358 | $9,961 | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.